Abingworth’s Hyperion Therapeutics HPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
– Sell
-62,500
Closed -$2.87M – 19
2015
Q1
$2.87M Hold
62,500
– – 1.22% 12
2014
Q4
$1.5M Hold
62,500
– – 0.43% 13
2014
Q3
$1.58M Hold
62,500
– – 0.94% 11
2014
Q2
$1.63M Hold
62,500
– – 0.76% 10
2014
Q1
$1.61M Hold
62,500
– – 0.89% 11
2013
Q4
$1.26M Hold
62,500
– – 0.95% 10
2013
Q3
$1.63M Hold
62,500
– – 0.93% 10
2013
Q2
$1.38M Hold
62,500
– – 1.06% 9

Abingworth's HPTX Position: Q2 2015 in Review

Abingworth sold out of Hyperion Therapeutics (HPTX) in Q2 2015, closing a stake of 62,500 shares — an estimated $2.87M sold.

Abingworth first reported a position in HPTX in Q2 2013 and held it in 8 quarters. The position peaked at $2.87M in Q1 2015. 0 funds tracked by Wall St. Rank hold HPTX as of Q2 2015.

  • Abingworth reported no remaining Hyperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Abingworth sold 62,500 Hyperion Therapeutics shares in Q2 2015, an estimated $2.87M.
  • Abingworth first reported a position in Hyperion Therapeutics in Q2 2013 and held it in 8 quarters.
  • Abingworth's Hyperion Therapeutics position peaked at $2.87M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Hyperion Therapeutics as of Q2 2015.

Based on Abingworth's 13F filing for Q2 2015, filed 14 Aug 2015.